Sanofi Q1 2025 Financial Report Analysis: Revenue Growth of 9.7%, Driven by Dupixent and Innovative Drugs

On April 24, Sanofi released its Q1 2025 financial report, with several key indicators showing strong performance. The report revealed that the company's Q1 sales reached €9.895 billion, a 9.7% year-over-year increase (CER), far exceeding market expectations. Among them, the flagship product Dupixent (dupilumab) saw a 20.3% increase in sales to €3.48 billion, and the innovative drug pipeline continued to deliver value, driving a 15.7% year-over-year increase in earnings per share (EPS) to €1.79. Based on this strong start, Sanofi confirmed its full-year guidance of mid-to-high single-digit sales growth and low double-digit EPS growth.

Core Financial Data: Dual Engine of Innovative Drugs and Vaccines

Revenue and Profit Growth

Sanofi's Q1 revenue grew by 10.8% year-over-year (CER +9.7%), mainly driven by the strong performance of its innovative drug and vaccine businesses. Business operating income (BOI) reached €2.902 billion, up 18.7%, with a profit margin increasing to 29.3%. Free cash flow was €1.029 billion, reflecting ongoing operational efficiency improvements.

Performance of Flagship Products

Dupixent: Global sales reached €3.48 billion (+20.3%), with expanded indications for chronic obstructive pulmonary disease (COPD), further opening markets after approval in Japan.

Innovative Drug Pipeline: Newly launched drugs (e.g., ALTUVIIIO, Nexviazyme) contributed a total of €847 million in sales, up 43.8%. Among them, the new hemophilia A drug ALTUVIIIO generated €251 million in sales (+100%), making it a potential "blockbuster".

Vaccine Business: Thanks to the promotion of the RSV vaccine Beyfortus, vaccine sales totaled €1.326 billion (+11.4%).

Other Product Performance: Receivables from other products showed positive results.

Regional Market Performance

U.S. Market (47% share) grew by 15.4%, driven primarily by Dupixent and innovative drugs.

European Market (21% share) saw a slight increase of 0.5%, impacted by competition from generics.

Chinese Market (7% of global share) declined by 1.7%, mainly due to pressure from healthcare negotiations and centralized procurement policies.

R&D and Pipeline Progress: 6 Approvals, Breakthroughs in Immunology

Sanofi obtained 6 regulatory approvals worldwide in Q1, covering immunology, rare diseases, and oncology:

• Dupixent: Approved for COPD indications in Japan and the EU, and submitted to the FDA for treatment of bullous pemphigoid (BP) in the U.S.
• Qfitlia (new drug for hemophilia A/B): Approved by the FDA in March, expected to begin sales in Q2.
• Sarclisa (multiple myeloma): Approved for new indications in China and the EU, driving a 26.4% increase in sales.

Additionally, mid-stage pipeline data is promising, such as amlitelimab (OX40L monoclonal antibody) showing a 70% reduction in acute asthma exacerbations in phase II trials, with phase III studies set to start; duvakitug (TL1A monoclonal antibody) showing significant efficacy in ulcerative colitis and Crohn’s disease, with phase III planned for the second half of the year.

Capital Operations and Sustainability

Strategic Acquisitions and Divestitures

Sanofi has agreed to acquire the clinical-stage bispecific antibody DR-0201, strengthening its immunology pipeline. It also plans to complete the sale of a majority stake in its consumer health business Opella in Q2, with the transaction amount undisclosed. The company has completed 72% of its planned €5 billion share buyback for 2025.

ESG Strategy Upgrades

Sanofi launched its new sustainability strategy "AIR," focusing on healthcare accessibility, environmental carbon reduction, and healthcare system resilience. The company aims to achieve net-zero emissions by 2045, with 70% of its product portfolio targeting diseases affected by climate change.

Management Outlook: Strong Confidence for the Year

Sanofi CEO Paul Hudson stated, "2025 has started strongly, with innovation investments and pipeline value releases being the core drivers of growth. Continued ramp-up of Dupixent and ALTUVIIIO, as well as the expansion into new indications like COPD, will lay the foundation for growth throughout the year." The company confirmed its full-year 2025 guidance:

• Sales: Mid-to-high single-digit CER growth.
• Business EPS: Low double-digit CER growth (before share buybacks).

Risks and Challenges

Despite strong performance, Sanofi still faces competition from generics (e.g., Lovenox, with European sales down 6.5%), policy pressures in the Chinese market, and the potential impact of the Zantac lawsuit (with most settlements reached in Q1, without admitting liability).

Conclusion

Through its "innovation + acquisitions" dual strategy, Sanofi has established differentiated advantages in immunology and rare diseases. With pipeline value gradually being realized and capital allocation optimized, the company is poised to achieve sustainable growth in 2025, creating long-term value for patients and shareholders.